The most notable insider activity on today's list comes via a Form 4 filing by Liberty 77 Fund.
The private equity fund, which manages approximately $2.95 billion in assets, reported a purchase of $1.2 million in Lions Gate Entertainment Corp $LGF.
Many times these transactions make sense only to buyers in the context of their investing or trading strategies.
With regard to LGF, for example, as technicians we prefer to wait until the chart looks more promising to us. This is not the case right now.
Here’s The Hot Corner, with data from October 9, 2024:
The most notable insider activity on today's list comes via a 13D filing by Baker Bros Advisors.
The hedge fund increased its ownership stake in Kiniksa Pharmaceuticals $KNSA from 6.94% to 7.70%.
Baker Bros' top holdings include BeiGene, Incyte, and Acadia Pharmaceuticals. These three positions represent roughly 50% of its portfolio.
We keep a close eye on what Baker Bros is up to -- the firm is better than anyone when it comes to biotech investing. It has a knack for spotting early-stage winners and sticking with them.
Its increased stake in KNSA means Baker Bros thinks this one will be a winner in the future.
We agree.
Here’s The Hot Corner, with data from October 8, 2024:
The most significant insider activity on today's list comes via a 13D filing by Mubadala Investment Company.
The sovereign wealth fund, which manages a portfolio for the government of Abu Dhabi, reported an initial stake of 9.50% in Equinox Gold Corp $EQX.
The fund's top holdings include GlobalFoundries and Evotec SE.
It’s not uncommon for insiders to buy stocks when they’re still in the accumulation or base-building phase. We see them buy downtrends and beaten-up names all the time as well.
What we don’t see as much is insiders stepping in and reporting a brand-new stake just as a fresh trend reversal is shaping up.
That’s what is happening here with EQX and Mubadala’s $230 million investment.
Here’s The Hot Corner, with data from October 7, 2024: